nach oben

The European Journal of Health Economics

Erschienen in:

26.05.2017 | Original Paper

Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan

verfasst von: Shota Saito, Motoi Azumi, Yusuke Muneoka, Katsuhiko Nishino, Takashi Ishikawa, Yuichi Sato, Shuji Terai, Kouhei Akazawa

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

A combination of assays for the presence of serum anti-Helicobacter pylori IgG antibody (HPA) and serum pepsinogen (PG) concentrations can be used to screen for gastric cancer risk. In Japan, this “ABC method” is considered an effective means of stratifying gastric cancer risk. This study aimed to ascertain its cost-effectiveness for assessing gastric cancer risk.

Methods

A Markov model was constructed to compare the cost-effectiveness of two strategies for gastric cancer-risk screening over a 30-year period: the ABC method, which uses a combination of assessing the presence of HPA and measuring serum PG concentrations and scheduling endoscopies accordingly, and annual endoscopic screening. Clinical and epidemiological data on variables in the model were obtained from published reports. Analyses were made from the perspective of the Japanese health care payer.

Results

According to base-case analysis, the ABC method cost less than annual endoscopic screening (64,489 vs. 64,074 USD) and saved more lives (18.16 vs. 18.30 quality-adjusted life years). One-way analyses confirmed the robustness of the cost-effectiveness results. The probability that the ABC method is cost-effective in Japanese individuals aged 50 years was 0.997.

Conclusions

A combination of HPA and serum PG assays, plus scheduling endoscopy accordingly, is a cost-effective method of screening for gastric cancer risk in Japan.

Nur mit Berechtigung zugänglich

International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/ (2012). Accessed 26 Mar 2015

National Cancer Center: Center for Cancer Control and Information Service. http://ganjoho.jp/reg_stat/statistics/dl/index.html (2014). Accessed 30 August 2015

Haga, K., Matsumoto, K., Kitazawa, T., et al.: Cost of illness of the stomach cancer in Japan—a time trend and future projections. BMC Health Serv. Res. (2013). doi:10.1186/1472-6963-13-283 PubMedPubMedCentral

Uemura, N., Okamoto, S., Yamamoto, S., et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784–789 (2001)CrossRefPubMed

Ford, A.C., Forman, D., Hunt, R.H., et al.: Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ (2014). doi:10.1136/bmj.g3174

Watabe, H., Mitsushima, T., Yamaji, Y., et al.: Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54, 764–768 (2005)CrossRefPubMedPubMedCentral

Ikeda, F., Shikata, K., Hata, J., et al.: Combination of Helicobacter pylori antibody and serum pepsinogen as a good predictive tool of gastric cancer incidence: 20-year prospective data from the Hisayama Study. J. Epidemiol. 26, 629–636 (2016)CrossRefPubMed

Sasazuki, S.: The ABC method and gastric cancer: evidence from prospective studies. J. Epidemiol. 26, 611–612 (2016)CrossRefPubMedPubMedCentral

Terasawa, T., Nishida, H., Kato, K., et al.: Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One 14, e109783 (2014)CrossRef

10.

Miki, K.: Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels–“ABC method”. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 87, 405–414 (2011)CrossRefPubMedPubMedCentral

11.

Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan.: Japanese Guideline for Gastric Cancer Screening 2014. http://canscreen.ncc.go.jp/guideline/igan.html (2014). Accessed 30 August 2014

12.

Yeh, J.M., Hur, C., Ward, Z., et al.: Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut (2015). doi:10.1136/gutjnl-2014-308588. (Epub ahead of print) PubMedCentral

13.

Shin, D.W., Yun, Y.H., Choi, I.J., et al.: Cost-effectiveness of eradication of Helicobacter pylori in gastric cancer survivors after endoscopic resection of early gastric cancer. Helicobacter. 14, 536–544 (2009)CrossRefPubMed

14.

Lansdorp-Vogelaar, I., Sharp, L.: Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract. Res. Clin. Gastroenterol. 27, 933–947 (2013)CrossRefPubMed

15.

Asaka, M., Kato, M., Graham, D.Y.: Strategy for eliminating gastric cancer in Japan. Helicobacter. 15, 486–490 (2010)CrossRefPubMedPubMedCentral

16.

Gotoda, T., Ishikawa, H., Ohnishi, H., et al.: Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy. Gastric Cancer 18, 605–611 (2015)CrossRefPubMed

17.

Hamashima, C., Ogoshi, K., Okamoto, M., et al.: A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One 8, e79088 (2013)CrossRefPubMedPubMedCentral

18.

Cancer Information Service, National Cancer Center, Japan.: Cancer Registry and Statistics. http://ganjoho.jp/reg_stat/statistics/dl/index.html (2016). Accessed 26 March 2015

19.

Sasaki, H., Nagahara, A., Hojo, M., et al.: Ten-year trend of the cumulative Helicobacter pylori eradication rate for the ‘Japanese eradication strategy’. Digestion. 88, 27–28 (2013)CrossRef

20.

Lee, Y.C., Chiang, T.H., Chou, C.K., et al.: Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology (2016). doi:10.1053/j.gastro.2016.01.028

21.

Miki K.: Manual for gastric cancer risk-screening with ABC-method in Japan. (2nd edition), Tokyo (2014) (in Japanese)

22.

Cancer Information Service, National Cancer Center, Japan.: Cancer Registry and Statistics. http://ganjoho.jp/reg_stat/statistics/dl/index.html (2015). Accessed 26 March 2015

23.

Hamashima, C., Okamoto, M., Shabana, M., et al.: Sensitivity of endoscopic screening for gastric cancer by the incidence method. Int. J. Cancer 133, 653–659 (2013)CrossRefPubMed

24.

Yoshino, J.: 5th report of endoscopic complications: results of the Japan Gastroenterological Endoscopy Society survey from 2003 to 2007. Gastroenterol Endosc. 52, 95–103 (2010). (in Japanese)

25.

Hori, M., Matsuda, T., Shibata, A., et al.: Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol. 45, 884–891 (2015)CrossRefPubMed

26.

Dan, Y.Y., So, J.B., Yeoh, K.G.: Endoscopic screening for gastric cancer. Clin. Gastroenterol. Hepatol. 4, 709–716 (2006)CrossRefPubMed

27.

Nashimoto, A., Akazawa, K., Isobe, Y., et al.: Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 16, 1–27 (2013)CrossRefPubMed

28.

Statistic Bureau, Ministry of Internal Affairs and Communications: Mortality rates by age group for Japan, 2015. Tokyo http://www.stat.go.jp/data/nihon/back15/02.htm (2017). Accessed 15 March 2017

29.

Jihou Press.: Medicinal Supplies Price List, Tokyo (2014) (in Japanese)

30.

Jihou Press.: National Health Insurance Price List, Tokyo (2014) (in Japanese)

31.

Statistics and Information Department, Minister’s Secretariat, Ministry of Health, Labour, and Welfare: National health expenditures for Japan, 2014. Tokyo http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/14/ (2015). Accessed 15 March 2017

32.

Organization for Economic Co-operation and Development.: Monthly Monetary and Financial Statistics (MEI): Exchange rates (USD monthly averages). http://stats.oecd.org/index.aspx?queryid=169 (2015). Accessed 26 March 2015

33.

Areia, M., Alves, S., Brito, D., et al.: Health-related quality of life and utilities in gastric premalignant conditions and malignant lesions: a multicentre study in a high prevalence country. J. Gastrointest. Liver Dis. 23, 371–378 (2014)

34.

Shiroiwa, T., Fukuda, T., Ikeda, S., et al.: Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res 25, 707–719 (2016)CrossRefPubMed

35.

Shiroiwa, T., Sung, Y.K., Fukuda, T., et al.: International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 19, 422–437 (2010)CrossRefPubMed

36.

Fukuda, T., Shiroiwa, T., Ikeda, S., et al.: Guideline for economic evaluation of healthcare technologies in Japan. National Institute of Public Health. J Natl Inst Public Health 62, 625–640 (2013). (in Japanese)

37.

de González, Berrington: A, Darby S.: risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 31, 345–351 (2004)CrossRef

38.

Yamaguchi, Y., Nagata, Y., Hiratsuka, R., et al.: Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG Antibody and serum pepsinogen levels-the ABC method. Digestion. 93, 13–18 (2016)CrossRefPubMed

39.

The Japanese Society for Helicobacter Research. Guideline of diagnosis and treatment for H. pylori infection. 2016 SENTAN IGAKU-SYA, Tokyo. (Japanese)

40.

Agkoc, M., Dursun, H., Albayrak, F., et al.: Usefulness of serum pepsinogen levels as a screening test for atrophic gastritis and gastric cancer. Eurasian J. Med. 42, 15–18 (2010)CrossRefPubMedPubMedCentral

41.

Wever, E.M., Draisma, G., Heijnsdijk, E.A., et al.: How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening. Med. Decis. Mak. 31, 550–558 (2011)CrossRef

42.

O’Connor, A., O’Morain, C.A., Ford, A.C.: Population screening and treatment of Helicobacter pylori infection. Nat. Rev. Gastroenterol. Hepatol. (2017). doi:10.1038/nrgastro.2016.195 PubMed

43.

Xie, F., O’Reilly, D., Ferrusi, I.L., et al.: Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J. Am. Coll. Radiol. 6, 317–323 (2009)CrossRefPubMed

Titel: Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan
verfasst von: Shota Saito
Motoi Azumi
Yusuke Muneoka
Katsuhiko Nishino
Takashi Ishikawa
Yuichi Sato
Shuji Terai
Kouhei Akazawa
Publikationsdatum: 26.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 4/2018
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-017-0901-y

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Determinants of catastrophic health expenditure in Nigeria

What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews

The financial performance of the health care industry: a global, regional and industry specific empirical investigation

Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment

Primary care supply and quality of care in England

Incorporating equity in economic evaluations: a multi-attribute equity state approach